Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease I: Introduction01:25

Peptic Ulcer Disease I: Introduction

Peptic ulcer disease (PUD) involves breaks in the gastrointestinal tract's mucosal lining, primarily in the stomach and duodenum, with less frequent occurrences in the lower esophagus or near the pylorus.Ulcers can be acute or chronic. Acute ulcers are short-lived with minimal inflammation and heal quickly after the irritant is removed. Chronic ulcers persist, may recur, and often cause scarring due to ongoing tissue damage. Superficial erosions affect only the mucosal layer and are called...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choosing a Prokinetic.

The American journal of gastroenterology·2020
Same author

Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasic patients with chronic pancreatitis. An update.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2017
Same author

Low Alcohol and Cigarette Use Is Associated to the Risk of Developing Chronic Pancreatitis.

Pancreas·2016
Same author

Role of Probiotics in Crohn's Disease and in Pouchitis.

Journal of clinical gastroenterology·2015
Same author

Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion.

Journal of clinical gastroenterology·2015
Same author

Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: Preliminary clinical experience.

Current therapeutic research, clinical and experimental·2014

Related Experiment Video

Updated: May 9, 2026

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Steroid ulcers: Any news?

Mario Guslandi1

  • 1Mario Guslandi, Gastroenterology Unit, S.Raffaele Hospital, Milan 20132, Italy.

World Journal of Gastrointestinal Pharmacology and Therapeutics
|August 7, 2013
PubMed
Summary
This summary is machine-generated.

Steroid-induced ulcers are rare in patients, contrary to experimental findings. Combining corticosteroids with NSAIDs significantly increases ulcer risk, necessitating careful consideration of prophylactic strategies.

Keywords:
CortcosteroidsPeptic ulcerProton pump inhibitors

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Related Experiment Videos

Last Updated: May 9, 2026

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Steroid ulcers are frequently observed in experimental settings but rarely in clinical practice.
  • Meta-analyses from the 1990s indicated a low incidence of steroid-induced ulcers in patients.
  • Corticosteroids alone typically require prolonged treatment (>1 month) and high doses (>1000 mg) to become ulcerogenic.

Purpose of the Study:

  • To evaluate the clinical relevance of steroid-induced ulcers.
  • To assess the risk factors associated with corticosteroid-induced gastroduodenal ulcers.
  • To determine the necessity and optimal strategy for pharmacological protection against steroid-induced peptic ulcers.

Main Methods:

  • Review of meta-analyses data from the 1990s concerning steroid-induced ulcers.
  • Analysis of the conditions under which corticosteroids alone induce ulceration.
  • Evaluation of the synergistic effects of concomitant non-steroidal anti-inflammatory drug (NSAID) use with corticosteroids on gastroduodenal mucosa.

Main Results:

  • Steroid ulcers are seldom observed in clinical practice despite being common in experimental studies.
  • Corticosteroids alone are ulcerogenic only with prolonged use (>1 month) and high cumulative doses (>1000 mg).
  • Concomitant use of NSAIDs with corticosteroids demonstrates a synergistic, highly damaging effect on the gastroduodenal mucosa.

Conclusions:

  • The 'steroid ulcer myth' persists in medical culture, but pharmacological protection is rarely necessary for steroid-induced peptic ulcers.
  • The combination of corticosteroids and NSAIDs poses a significant risk to the gastroduodenal mucosa.
  • The optimal prophylactic strategy for preventing steroid-induced peptic ulcers requires further determination.